167 related articles for article (PubMed ID: 37879723)
21. Association between Industry Payments and Anti-vascular Endothelial Growth Factor Use in Medicare Beneficiaries.
Mahr MA; Hodge DO; Erie JC
Ophthalmol Retina; 2017; 1(1):19-24. PubMed ID: 31047391
[TBL] [Abstract][Full Text] [Related]
22. Association between industry payments and prescriptions of long-acting insulin: An observational study with propensity score matching.
Inoue K; Tsugawa Y; Mangione CM; Duru OK
PLoS Med; 2021 Jun; 18(6):e1003645. PubMed ID: 34061852
[TBL] [Abstract][Full Text] [Related]
23. Association of Industry Payments to Physicians With the Prescribing of Brand-name Statins in Massachusetts.
Yeh JS; Franklin JM; Avorn J; Landon J; Kesselheim AS
JAMA Intern Med; 2016 Jun; 176(6):763-8. PubMed ID: 27159336
[TBL] [Abstract][Full Text] [Related]
24. Types and Distribution of Payments From Industry to Physicians in 2015.
Tringale KR; Marshall D; Mackey TK; Connor M; Murphy JD; Hattangadi-Gluth JA
JAMA; 2017 May; 317(17):1774-1784. PubMed ID: 28464140
[TBL] [Abstract][Full Text] [Related]
25. Effect of Denosumab Added to 2 Different nab-Paclitaxel Regimens as Neoadjuvant Therapy in Patients With Primary Breast Cancer: The GeparX 2 × 2 Randomized Clinical Trial.
Blohmer JU; Link T; Reinisch M; Just M; Untch M; Stötzer O; Fasching PA; Schneeweiss A; Wimberger P; Seiler S; Huober J; Thill M; Jackisch C; Rhiem K; Solbach C; Hanusch C; Seither F; Denkert C; Engels K; Nekljudova V; Loibl S;
JAMA Oncol; 2022 Jul; 8(7):1010-1018. PubMed ID: 35588050
[TBL] [Abstract][Full Text] [Related]
26. The impact of reducing pharmaceutical industry payments on physician prescribing.
Parker-Lue S
Health Econ; 2020 Mar; 29(3):382-390. PubMed ID: 31930636
[TBL] [Abstract][Full Text] [Related]
27. Physician Payments from Industry Are Associated with Greater Medicare Part D Prescribing Costs.
Perlis RH; Perlis CS
PLoS One; 2016; 11(5):e0155474. PubMed ID: 27183221
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of Sex Distribution of Industry Payments Among Radiation Oncologists.
Weng JK; Valle LF; Nam GE; Chu FI; Steinberg ML; Raldow AC
JAMA Netw Open; 2019 Jan; 2(1):e187377. PubMed ID: 30681710
[TBL] [Abstract][Full Text] [Related]
29. Industry Payment to Vascular Neurologists: A 6-Year Analysis of the Open Payments Program From 2013 Through 2018.
Nalleballe K; Sheng S; Li C; Mahashabde R; Annapureddy AR; Mudassar K; Pothineni K; Veerapaneni P; Harada Y; Chilkulwar A; Ranabothu S; Brown A; Kapoor N; Onteddu S
Stroke; 2020 Apr; 51(4):1339-1343. PubMed ID: 32078482
[TBL] [Abstract][Full Text] [Related]
30. Association of Participation in the Oncology Care Model With Medicare Payments, Utilization, Care Delivery, and Quality Outcomes.
Keating NL; Jhatakia S; Brooks GA; Tripp AS; Cintina I; Landrum MB; Zheng Q; Christian TJ; Glass R; Hsu VD; Kummet CM; Woodman S; Simon C; Hassol A;
JAMA; 2021 Nov; 326(18):1829-1839. PubMed ID: 34751709
[TBL] [Abstract][Full Text] [Related]
31. Industry Payments to Physicians and Prescribing Branded Memantine and Donepezil Combination.
Marcum ZA; Chang CY; Barthold D; Holmes HM; Lo-Ciganic WH
Neurol Clin Pract; 2021 Jun; 11(3):181-187. PubMed ID: 34484885
[TBL] [Abstract][Full Text] [Related]
32. Association of Device Industry Payments, Physician Supply, and Regional Utilization of Orthopedic and Cardiac Procedures.
Muluk SL; Lin GA; Anderson TS
J Gen Intern Med; 2023 Aug; 38(11):2501-2510. PubMed ID: 36952081
[TBL] [Abstract][Full Text] [Related]
33. The Association between Industry Payments and Brand-Name Prescriptions in Otolaryngologists.
Morse E; Hanna J; Mehra S
Otolaryngol Head Neck Surg; 2019 Oct; 161(4):605-612. PubMed ID: 31547772
[TBL] [Abstract][Full Text] [Related]
34. Industry Payments to Physician Specialists Who Prescribe Repository Corticotropin.
Hartung DM; Johnston K; Cohen DM; Nguyen T; Deodhar A; Bourdette DN
JAMA Netw Open; 2018 Jun; 1(2):e180482. PubMed ID: 30646086
[TBL] [Abstract][Full Text] [Related]
35. Association Between Industry Marketing Payments and Prescriptions for PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibitors in the United States.
Inoue K; Figueroa JF; DeJong C; Tsugawa Y; Orav EJ; Shen C; Kazi DS
Circ Cardiovasc Qual Outcomes; 2021 May; 14(5):e007521. PubMed ID: 33966446
[TBL] [Abstract][Full Text] [Related]
36. Public Awareness of and Contact With Physicians Who Receive Industry Payments: A National Survey.
Pham-Kanter G; Mello MM; Lehmann LS; Campbell EG; Carpenter D
J Gen Intern Med; 2017 Jul; 32(7):767-774. PubMed ID: 28265803
[TBL] [Abstract][Full Text] [Related]
37. Industry payments to US physicians for cancer therapeutics: An analysis of the 2016-2018 open payments datasets.
Meyers DE; Chisamore TM; McInnes MDF; Gyawali B; Prasad V; Booth CM
J Cancer Policy; 2021 Jun; 28():100283. PubMed ID: 35559912
[TBL] [Abstract][Full Text] [Related]
38. Association of Pharmaceutical Industry Payments to Physicians With Prescription and Medicare Expenditures for Pimavanserin.
Mehta HB; Moore TJ; Alexander GC
Psychiatr Serv; 2021 Jan; 72(1):77-80. PubMed ID: 32838675
[TBL] [Abstract][Full Text] [Related]
39. Pharmaceutical industry-sponsored meals are associated with increased prescriptions and Medicare spending for dupilumab among dermatologists in the United States.
Murayama A
J Eval Clin Pract; 2024 Apr; 30(3):435-439. PubMed ID: 38149692
[TBL] [Abstract][Full Text] [Related]
40. Industry payments and physicians prescriptions: Effect of a payment restriction policy.
Ansari B
Soc Sci Med; 2021 Jun; 278():113942. PubMed ID: 33892242
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
